RT Journal Article
SR Electronic
T1 Frailty Status Predicts New Long-term Care Insurance Certification in Hepatitis C Patients Receiving Antiviral Therapy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4127
OP 4131
DO 10.21873/anticanres.15215
VO 41
IS 8
A1 KENICHI NAKAMURA
A1 KAZUNORI KUSUMOTO
A1 YOSHINORI OZONO
A1 KAZUO KUROKI
A1 YUNOSUKE MATSUURA
A1 TOSHIHIRO MUKUDA
A1 TOSHIMASA OCHIAI
A1 MAI TSUCHIMOCHI
A1 HISAYOSHI IWAKIRI
A1 SATORU HASUIKE
A1 KAZUYA SHIMODA
A1 KENJI NAGATA
YR 2021
UL http://ar.iiarjournals.org/content/41/8/4127.abstract
AB Background/Aim: Direct-acting antiviral (DAA) therapies for patients with hepatitis C virus (HCV) infection deliver higher cure rates and lower frequencies of adverse events than existing therapies, though DAA treatment costs $45,000-64,000 in Japan. The prognosis of patients who require new long-term care insurance (LTCI) certification is inferior to that of patients who do not. Here, we clarify the factors associated with new LTCI certification in elderly patients with HCV infection who undergo DAA therapy. Patients and Methods: We retrospectively surveyed 53 patients aged ≥70 years who were treated with DAAs, and evaluated the factors associated with new LTCI certification. Results: Of 53 patients, 10 required new LTCI certification. Age ≥85 years and a modified Japanese Cardiovascular Health Study index ≥2 were independently associated with new LTCI certification. Conclusion: In elderly HCV patients, poor frailty status strongly predicted new LTCI certification after DAA therapy.